Projects per year
Abstract / Description of output
Activation of brown adipose tissue (BAT) in humans is a strategy to treat obesity and metabolic disease. Here, we show that the serotonin transporter SERT, encoded by SLC6A4, prevents serotonin-mediated suppression of human BAT function. RNA sequencing of human primary brown and white adipocytes shows that SLC6A4 is highly expressed in human, but not murine, brown adipocytes and BAT. Serotonin decreases uncoupled respiration and reduces uncoupling protein 1 via the 5-HT2B receptor. SERT inhibition by the selective serotonin reuptake inhibitor (SSRI) sertraline prevents uptake of extracellular serotonin, thereby potentiating serotonin’s suppressive effect on brown adipocytes. Furthermore, we see that sertraline reduces BAT activation in healthy volunteers, and SSRI-treated patients demonstrate no 18F-fluorodeoxyglucose uptake by BAT at room temperature, unlike matched controls. Inhibition of BAT thermogenesis may contribute to SSRI-induced weight gain and metabolic dysfunction, and reducing peripheral serotonin action may be an approach to treat obesity and metabolic disease.
Original language | English |
---|---|
Pages (from-to) | 1319-1336 |
Journal | Nature Metabolism |
Volume | 5 |
DOIs | |
Publication status | Published - 3 Aug 2023 |
Fingerprint
Dive into the research topics of 'The serotonin transporter sustains human brown adipose tissue thermogenesis'. Together they form a unique fingerprint.Projects
- 4 Finished
Equipment
-
Edinburgh Clinical Research Facility Mass Spectrometry Core in the QMRI
Natalie Homer (Manager), Scott Denham (Other) & Jo Simpson (Other)
Centre for Cardiovascular ScienceFacility/equipment: Facility
-
Edinburgh Imaging Facility
Anne Grant (Manager), Edwin van Beek (Manager) & Scott Semple (Manager)
Deanery of Clinical SciencesFacility/equipment: Facility
-
Image Analysis Core
Tom MacGillivray (Manager) & Calum Gray (Other)
Work Enabled by Edinburgh Clinical Research FacilityFacility/equipment: Facility